Zoetis (ZTS) Stock
Global animal health leader for pets and livestock. Here's the price, business snapshot, and what's worth knowing about Zoetis in August 2026.
Zoetis Inc. (ZTS) is a global leader in animal health, developing, manufacturing and commercialising medicines, vaccines and diagnostics for livestock and companion animals. With a market capitalisation of about $64.7bn, the company benefits from steady, recurring demand driven by pet ownership trends, livestock productivity needs and veterinary services growth across developed and emerging markets. Zoetis' strength lies in a diversified product portfolio, a broad geographic footprint and ongoing investment in R&D and targeted acquisitions to expand its pipeline. Investors should note potential advantages — predictable cash flows, margin resilience and dividend capacity — alongside risks such as regulatory scrutiny, pricing pressures, disease outbreaks and currency exposure. Zoetis may suit investors seeking exposure to defensive growth within healthcare, but it is important to assess valuation, portfolio fit and risk tolerance. This information is educational only and not personalised investment advice; values can rise or fall and past performance is not a guarantee of future returns.
Why It’s Moving
Zoetis is drawing renewed analyst attention as Wall Street weighs durable animal-health demand against slower growth expectations.
- Analysts continue to frame Zoetis as a steady animal-health name with room for a re-rating, even as recent target cuts show some caution around growth and pricing power.
- The latest analyst action came on 2026-08-07, signaling that investors are still digesting fresh Wall Street views rather than a new company catalyst.
- Broader sentiment remains constructive, with several analyst trackers showing buy-leaning coverage and double-digit upside implied from current levels.
Zoetis is drawing renewed analyst attention as Wall Street weighs durable animal-health demand against slower growth expectations.
- Analysts continue to frame Zoetis as a steady animal-health name with room for a re-rating, even as recent target cuts show some caution around growth and pricing power.
- The latest analyst action came on 2026-08-07, signaling that investors are still digesting fresh Wall Street views rather than a new company catalyst.
- Broader sentiment remains constructive, with several analyst trackers showing buy-leaning coverage and double-digit upside implied from current levels.
Sixth Month Growth Performance
When is the next earnings date for ZOETIS INC (ZTS)?
Zoetis’s next earnings report is expected on November 3, 2026, based on the company’s usual reporting pattern. It should cover Q3 2026 results. If the company confirms a different date, that would supersede the estimate.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Zoetis stock, with a target price suggesting substantial growth potential.
Financial Health
Zoetis Inc is performing well with strong profits and cash flow, indicating robust financial stability.
Dividend
Zoetis Inc's dividend yield of 2.28% is reasonable for investors seeking dividends. If you invested $1000 you would be paid $22.80 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Steady demand drivers
Rising pet ownership and livestock productivity needs can support predictable revenue, though sales can vary with animal health trends and outbreaks.
Global footprint
A wide geographic reach exposes Zoetis to growth in emerging markets, but also brings currency and regulatory risk across regions.
R&D and pipeline
Ongoing investment in R&D and selective acquisitions fuels future products, yet new launches carry execution and approval risks.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
